Table 1 Virus neutralization titers post single dose of BBV152 vaccination based on RBD-ELISA positivity.

From: Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination

 

Geometric mean FRNT50 (95% CI)

 

Sampling time

Baseline WT (A)

One dose WT (B)

P value comparing the titers within each group; before and after 1 dose of vaccine (A vs B) (Wilcoxon signed-rank test)

Baseline B.1.617.2 (C)

One dose B.1.617.2 (D)

P value comparing the titers within each group; before and after 1 dose of vaccine (C vs D) (Wilcoxon signed-rank test)

All (n = 94)

108.6 (81.3–145.1)

256.4 (196.1–335.3)

<0.0001

291.4 (209.6–405.0)

508.1 (398.9–647.2)

0.0126

Groups based on RBD-ELISA results

      

1. RBD-positive at baseline (n = 67)

182.8 (133.6–250.0)

422.2 (340.5–523.5)

0.0001

531.9 (371.6–761.2)

783.2 (624.8–981.7)

0.448

2. RBD-Negative at baseline (n = 23)

26.50 (19.8–35.5)

57.32 (33.0–99.6)

0.0033

63.94 (46.4–88.1)

146.6 (95.7–224.7)

0.0002

P value comparing the titers between 2 groups based on RBD-ELISA (using Wilcoxon rank-sum test)

<0.0001

<0.0001

 

<0.0001

<0.0001

 
  1. Comparison of GMTs (with 95% CI) of neutralizing antibodies at baseline and 4 weeks after 1st dose was performed using Wilcoxon signed-rank test. Comparison of GMTs between the groups (based on RBD-ELISA results) was performed  using the Wilcoxon rank-sum test. Two-tailed P values are  indicated.
Back to article page